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Introduction Methods 
Conclusions and Future Research 
We expect that PKC δ activation will attenuate PMA-induced PMN SO 
release, whereas PKC δ inhibition will augment the response in 
comparison to untreated controls. 
 
As expected, PKC δ+ attenuated PMN SO release up to 50%, whereas, 
rottlerin augmented the PMA response  up to 96% compared to untreated 
PMA controls (both p<0.05). However, the PKC δ- only enhanced PMN 
SO release up to 30%. Moreover, cell viability was >93±4% in all study 
groups suggesting that the effects of rottlerin, PKC δ-, and PKC δ+ on 
PMA induced SO release were not related to cell viability. The data 
suggest that PKC δ negatively regulates PMN NADPH oxidase SO 
release. PKC δ- is relatively ineffective in regulating PMN SO release 
compared to rottlerin. The data suggest that inhibiting the ATP binding 
site of PKC δ by rottlerin may be more effective than the inhibition of 
the translocation of PKC δ to PMN substrates such as NADPH oxidase. 
Preliminary data  shows that superoxide dismutase (SOD) inhibited 
untreated PMA (30 nM, n=3) induced SO release by 95±9% and also 
attenuated PMA plus rottlerin (20 μM, n=3) induced SO release by 
96±4%. Cell viability was 96±1% in SOD treated groups. These 
preliminary results suggests that the effects of rottlerin to augment the 
reduction of ferricytochrome c in the presence of PMA are related to the 
generation of SO release. Additional trials will be preformed to confirm 
the preliminary results. Further research will be aimed at determining the 
phosphorylation sites of p47phox by PKC δ. 
 
 
Results 
Isolation of PMNs 
Male Sprague-Dawley rats (350-400 g, Charles River), used as PMN 
donors, were anesthetized with 2.5% isoflurane and given a 16 ml 
intraperitoneal injection of 0.5% glycogen (Sigma Chemical) dissolved 
in PBS. Rats were reanesthetized with isoflurane 16-18 h later, and the 
PMNs were harvested by peritoneal lavage in 30 ml of 0.9% NaCl, as 
previously described [5,8]. Peritoneal lavage fluid was centrifuged at 
200 x g for 10 min at 4°C. Then, the PMNs were washed in 20 ml PBS 
and centrifuged at 200 g for 10 min at 4° C. PMNs were resuspended in 
2.5 mL PBS and density was calculated.  The PMNs preparation were 
>90% pure and >95% viable according to microscopic analysis and 0.3 
trypan blue exclusion, respectively.  
Measurement of SO release from Rat PMNs 
The SO release from PMNs was measured spectrophotometrically 
(model 260 Gilford, Nova Biotech; El Cajon, CA) by the reduction of 
ferricytochrome c [5,8]. The PMNs (5 x 106) were resuspended in 450 µl 
of PBS and incubated with ferricytochrome c (100 µM, Sigma 
Chemical) in a total volume of 900 µl PBS in the presence or absence of 
PKC δ activator (Myr-MRAAEDPM, MW=1130 g/mol, 2.5-20 µM, 
n=10-13), PKC δ inhibitor (Myr-SFNSYELGSL, MW=1326 g/mol, 1-20 
µM, n=7-10) or rottlerin (MW=516 g/mol, 0.625-20 µM, n=8-12) for 15 
min at 37°C in spectrophotometric cells. The PMNs were stimulated 
with 15 or 30 nM PMA (MW=616 g/mol, n=13-26) in a final reaction 
volume of 1.0 ml. Absorbance at 550 nm was measured every 30 sec for 
up to 420 sec for PMA and the change in absorbance (SO release) from 
PMNs was determined relative to time 0. Cell viability among all study 
groups was determined by 0.3% trypan blue exclusion at the end of SO 
release assay. Viable cells remained unstained and non-viable cells 
stained blue. 
Statistical Analysis 
All data in the text and figures are presented as means ± S.E.M. The 
data were analyzed by analysis of variance using post hoc analysis with 
Fishers PLSD test. Probability values of <0.05 are considered to be 
statistically significant. 
Hypothesis 
Figure 1. Inflammatory cytokines bind to PMN chemotactic receptors signaling 
PKC activation via DAG. p47phox is phosphorylated by  multiple PKC isoforms 
that can augment (α/βII/ζ) or inhibit (δ) the assembly of cytosolic subunits to the 
membranous components  of NADPH oxidase leading to activation or inhibition of 
activity. PKC δ+, a cell-permeable peptide, increases the translocation of PKC δ to 
cell substrates such as p47phox. PKC δ phosphorylation of PMN p47phox is 
associated with negative regulation preventing the assembly NADPH oxidase and 
thereby inhibiting SO (O2
-) release. By contrast, inhibiting PKC δ phosphorylation 
of p47phox with rottlerin or PKC δ- would augment PMA induced SO release. 
Recruitment and activation of PMNs and subsequent SO release 
contribute to inflammation mediated tissue injury such as that following 
ischemia/reperfusion (I/R). Therefore, identifying mechanisms that 
regulate PMN SO release may lead to therapies that mitigate PMN tissue 
injury. Phosphorylation of PMN NADPH oxidase by PKC is essential to 
generate SO release. There are 5 isoforms of PKC (alpha (α), beta I (βI), 
beta II (βII), delta (δ), and zeta (ζ)) expressed by PMNs which regulate 
NADPH oxidase activity by phosphorylation of p47phox (a component of 
the NADPH oxidase enzyme) (figure 1). It is known that PMA, a broad-
spectrum PKC activator which functions as a diacylglycerol (DAG) 
mimetic, augments SO release in PMNs via NADPH oxidase activation 
principally through βII, ζ, and to a lesser extent α activation [1]. 
Additionally, PKC δ activation is known to inhibit PMN elastase release 
which occurs during inflammation of activated PMNs [2]. To date, the 
roles of PKC δ in mediating inflammatory responses and leukocyte SO 
release in vivo remains unclear. Characterizing the role of various PKC 
isoforms would help elucidate the homeostatic balance of PKC regulating 
PMN NADPH oxidase and inflammation mediated I/R injury. 
We have previously shown that a cell-permeable PKC δ peptide activator 
(PKC δ+) facilitates the translocation of PKC δ to cell substrates via 
interaction with its specific receptor for activated C kinase (RACK) 
exhibited cardioprotection in a leukocyte aggravated myocardial I/R 
injury ex vivo model and attenuated NG-nitro-L-arginine-methyl-ester (L-
NAME) induced leukocyte endothelial interactions in mensenteric 
venules in vivo [3]. We speculate that PKC δ activation may also 
negatively regulate PMN SO release. Moreover, Inagaki et al, showed 
that activation of PKC δ mediates cardioprotective effects in myocardial 
I/R injury [4]. We propose that inhibiting PKC δ would augment PMN 
SO release. Therefore, using a PKC δ peptide inhibitor (PKC δ-) that 
inhibits the binding of PKC δ to its RACK, or rottlerin, a phenolic 
compound that is a selective inhibitor of PKC δ (IC50 3-6 µM) at its ATP 
binding site can be used to assess the role of PKC δ in the regulation of 
SO release in PMNs [5,6,7]. 
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Figure 2. Illustration of the mechanism and amino acid (aa) sequence of PKC δ 
isoform activator/inhibitor peptides, PKC δ inhibitor rottlerin, and the broad-
spectrum PKC activator PMA. The RACK-1 region is unique for PKC δ and is 
responsible for regulating the translocation of PKC δ from the cytosol to the cell 
membrane. The inhibitory region attenuates interaction of activated PKC δ for its 
RACK whereas the activator peptide augments interaction with PKC δ and its 
RACK. Both peptides are conjugated to myristric acid (Myr) at the N-terminus to 
facilitate cell permeability. Rottlerin is a lipid-soluble phenolic compound derived 
from the Mallotus philippinensis tree that is selective for inhibiting PKC δ at its ATP 
binding site. Finally, PMA is a lipid-soluble PKC agonist at the regulatory domain. 
 
Figure 4. Time course of PMA (15 nM) induced SO release in presence and 
absence of varying concentrations of PKC δ- 
PKC δ peptide inhibitor dose-dependently augmented PMA induced SO release by 
12±9% (10 μM) and 30±13% (20 μM) at 7 min respectively. 
 
Figure 5. Time course of PMA (30 nM) induced SO release in presence and 
absence of varying concentrations of PKC δ+ 
PKC δ peptide activator dose-dependently inhibited PMA induced SO release by 
48±12% (10 μM ) and 50±7% (20 μM) (both p<0.05 vs untreated controls) at 7 
min respectively.  
 
Figure 3. Time course of PMA (30 nM) induced SO release in presence and 
absence of varying concentrations of rottlerin 
Rottlerin dose-dependently augmented PMA induced SO release by  96±9% (10 
μM). The 20 μM dose augmented PMA induced SO release by 83±6% at 7 min 
(both p<0.05 compared to untreated control) at 7 min respectively.  
Figure 6. The effects of rottlerin, PKC δ peptide inhibitor, and PKC δ peptide 
activator (all 10 and 20 μM) on cell viability in PMA induced SO release assays. 
Untreated PMA controls, PKC δ peptide inhibitor, and PKC δ peptide activator 
showed 95±1% cell viability after SO release cell measurements. Rottlerin showed 
91±1% (10 μM) and 89±2% (20 μM) cell viability after SO release cell 
measurements. Lower doses of rottlerin that also showed significant augmentation 
in PMA SO release (see figure 3), had cell viability values 94±1%.  
